Business Overview: Interpace Biosciences, Inc. (OTCQX: IDXG)

---

Executive Summary

Interpace Biosciences, Inc. is a molecular diagnostics company that develops and sells esoteric diagnostic tests and pathology services to help physicians assess cancer risk in patients with indeterminate biopsy results. After the Centers for Medicare & Medicaid Services (CMS) ended reimbursement coverage for its pancreatic-cancer test PancraGEN on April 24, 2025 — leading the company to discontinue that product in May 2025 — Interpace is now effectively a pure-play thyroid cancer diagnostics company, built around its ThyGeNEXT and ThyraMIRv2 test panel.

Interpace is a small company trading on the OTCQX market, with preliminary 2025 revenue of roughly $38–39 million, nearly all of it now from thyroid testing (up about 21% year-over-year). In late 2025 the company repaid all of its outstanding debt and converted its Series C preferred shares into common stock, simplifying its capital structure ahead of a stated plan to seek a Nasdaq uplisting in 2026.

---

1. Core Business Model & How They Work

Interpace's model is a classic specialty-lab diagnostics business: develop a proprietary molecular test, get physicians (mainly endocrinologists and cytopathologists) to order it on ambiguous biopsy samples, run the test in-house, and bill payers per test.

[ Indeterminate Thyroid FNA Biopsy ] ➡️ [ ThyGeNEXT DNA/RNA Panel ] ➡️ [ ThyraMIRv2 microRNA Reflex (~85% of cases) ] ➡️ [ Malignancy Risk Result ] ➡️ [ Payer Billing ]

Key Operational Drivers

1. Reflex testing architecture: ThyGeNEXT (a DNA/RNA mutation and fusion panel) is run first; when results are ambiguous, the sample reflexes into ThyraMIRv2 (an 11-microRNA classifier) roughly 85% of the time, improving diagnostic confidence and effectively bundling two billable tests into one clinical workflow.
2. Reference-lab distribution: LabCorp was Interpace's largest customer in 2025 for its thyroid tests, giving the company national reach without having to build its own nationwide logistics network from scratch.
3. Direct sales force: A roughly 30-person sales team calls directly on endocrinologists, pathology groups, and cancer centers.
4. Payer-dependent, out-of-network billing: Interpace is currently out-of-network with most commercial payers, billing Medicare, Medicare Advantage, Medicaid, and direct clients, which makes reimbursement economics a persistent variable rather than a settled contract.

---

2. Business Segments

Interpace operates as a single reportable segment — developing and selling diagnostic clinical services. A segment breakdown is not meaningful; the discontinuation of PancraGEN in May 2025 further concentrated the business into one product line (thyroid testing).

---

3. Product Portfolio

---

4. Competitive Landscape

Interpace competes in the U.S. thyroid molecular diagnostics market, which it estimates at roughly $300 million annually, against better-capitalized, more broadly reimbursed rivals:

• Veracyte (Afirma): The acknowledged market leader in thyroid molecular testing, with the deepest payer coverage and clinical validation data.
• Quest Diagnostics: Offers a test similar to an earlier ThyGeNEXT generation and separately distributes Veracyte's Afirma, putting it on both sides of the competitive map.
• Sonic Healthcare (ThyroSeq): Uses next-generation sequencing to profile genetic alterations in thyroid nodules.
• Institutional/local tests: Some hospital systems and academic centers run their own laboratory-developed tests rather than referring out, a quieter but persistent source of volume loss.

         THYROID DX COMPETITIVE POSITIONING
┌─────────────────────────────────────────────┐
│ High │                                        │
│      │        [Veracyte Afirma]               │
│Payer │                    [Sonic ThyroSeq]     │
│Cover-│                                        │
│ age  │   [Quest]                               │
│      │          [Interpace ThyGeNEXT/ThyraMIR] │
│ Low  │                                        │
│      └────────────────────────────────────────►
│        Small / Niche      Scale        Large   │
└─────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Focused clinical niche: ThyGeNEXT/ThyraMIRv2's reflex-testing design gives physicians a single, reasonably differentiated workflow for indeterminate thyroid nodules rather than competing purely on price.
• National distribution via LabCorp: Partnering with the country's largest reference lab gives a small company access to ordering physicians it could not reach alone.
• Simplified, deleveraged balance sheet: Repaying all outstanding debt and converting Series C preferred stock to common in late 2025 removed overhangs that had complicated the capital structure and investor story.

Risks

1. Single-payer concentration precedent: The PancraGEN discontinuation — triggered entirely by one CMS coverage decision — is a direct demonstration of how dependent Interpace's revenue is on individual reimbursement determinations; the same risk now sits entirely on thyroid testing.
2. Out-of-network status: Being out-of-network with most commercial payers means reimbursement per test is less predictable and often lower than an in-network competitor would receive.
3. Market leader headwind: Veracyte's Afirma has stronger brand recognition and payer coverage in the same niche, limiting Interpace's ability to win share on reputation alone.
4. Scale and capital constraints: As an OTCQX-listed micro-cap, Interpace has far less capital for sales force expansion, clinical studies, or payer contracting than Veracyte or Sonic Healthcare.
5. Uplisting is not guaranteed: Management's stated 2026 Nasdaq uplisting plan depends on meeting listing standards and market conditions that are outside the company's full control.

---

6. Financial Overview

---

7. Summary Conclusion

Interpace is a small, single-product-line diagnostics company that has just been forced to prove, the hard way, how exposed a molecular-testing business can be to a single payer's coverage decision — the loss of PancraGEN overnight concentrated the entire business onto ThyGeNEXT/ThyraMIRv2 thyroid testing. The thyroid franchise is real and growing at a healthy clip against a credible but not dominant competitive position versus Veracyte's Afirma, and management has used 2025 to clean up the balance sheet (debt repayment, preferred conversion) ahead of a Nasdaq uplisting push. The central question for Interpace going forward is whether a single-product, out-of-network, sub-$40-million-revenue diagnostics company can keep growing share against far better-funded competitors before the next reimbursement shock arrives.